Bristol Myers Squibb presented new two-year data for Sotyktu (deucravacitinib). The data comes from its Phase 3 POETYK PsA-2 study. The study involved adults with active psoriatic arthritis.
The company shared these results at the Congress of Clinical Rheumatology - West. The data stems from an open-label extension of the trial.
The study demonstrated Sotyktu's durable efficacy. Clinical responses improved through the first year. These responses remained through the second year.
The drug showed a consistent long-term safety profile. Researchers identified no new safety signals.
These findings strengthen the evidence for Sotyktu. It is a viable long-term oral treatment option for the chronic disease.